<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Mon, 14 Oct 2024 18:14:02 +0000</lastbuilddate>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Focus on ischaemic heart disease: secondary prevention, cardiogenic shock, and novel therapeutic targets</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39400274/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 14;45(39):4141-4144. doi: 10.1093/eurheartj/ehae689.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39400274/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39400274</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae689>10.1093/eurheartj/ehae689</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39400274</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on ischaemic heart disease: secondary prevention, cardiogenic shock, and novel therapeutic targets</dc:title>
<dc:identifier>pmid:39400274</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae689</dc:identifier>
</item>
<item>
<title>Plasma proteome and incident myocardial infarction: sex-specific differences</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39397782/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study identified both new and confirmed previously established associations between circulating proteins and incident MI and, for the first time, suggested sex-specific patterns in multiple protein-MI associations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 14:ehae658. doi: 10.1093/eurheartj/ehae658. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Few population-based cohort studies, including both men and women, have explored circulating proteins associated with incident myocardial infarction (MI). This study investigated the relationships between circulating cardiometabolic-related proteins and MI risk using cohort-based and Mendelian randomization (MR) analyses and explored potential sex-specific differences.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The discovery cohort included 11 751 Swedish adults (55-93 years). Data on 259 proteins assessed with Olink proximity extension assays, biochemical, and questionnaire-based information were used. Participants were followed up for incident MI and death over 8 years through linkage to Swedish registers. Replication analyses were conducted on the UK Biobank sample (n = 51 613). In MR analyses, index cis-genetic variants strongly related to the proteins were used as instrumental variables. Genetic association summary statistic data for MI were obtained from the CARDIoGRAMplusC4D consortium and FinnGen.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Forty-five proteins were associated with incident MI in discovery and replication samples following adjustment for potential confounders and multiple testing. In the secondary analysis, 13 of the protein associations were sex-specific, with most associations identified among women. In MR analysis, genetically predicted higher levels of renin, follistatin, and retinoic acid receptor responder protein 2 were linked to an increased risk of MI. Tissue factor pathway inhibitor, tumor necrosis factor receptors 1 and 2, placenta growth factor had an inverse association with MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study identified both new and confirmed previously established associations between circulating proteins and incident MI and, for the first time, suggested sex-specific patterns in multiple protein-MI associations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39397782/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39397782</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae658>10.1093/eurheartj/ehae658</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39397782</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Olga E Titova</dc:creator>
<dc:creator>Shuai Yuan</dc:creator>
<dc:creator>Liisa Byberg</dc:creator>
<dc:creator>John A Baron</dc:creator>
<dc:creator>Lars Lind</dc:creator>
<dc:creator>Karl Michaëlsson</dc:creator>
<dc:creator>Susanna C Larsson</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Plasma proteome and incident myocardial infarction: sex-specific differences</dc:title>
<dc:identifier>pmid:39397782</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae658</dc:identifier>
</item>
<item>
<title>Steps towards curing Yentl syndrome: appraising sex differences in circulating proteins and incident myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39397778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 14:ehae657. doi: 10.1093/eurheartj/ehae657. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39397778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39397778</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae657>10.1093/eurheartj/ehae657</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39397778</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Anna K Barton</dc:creator>
<dc:creator>Emily S Lau</dc:creator>
<dc:creator>Martha Gulati</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Steps towards curing Yentl syndrome: appraising sex differences in circulating proteins and incident myocardial infarction</dc:title>
<dc:identifier>pmid:39397778</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae657</dc:identifier>
</item>
<item>
<title>Atrioventricular node ablation for atrial fibrillation in the era of conduction system pacing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39397777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>Despite key advances in catheter-based treatments, the management of persistent atrial fibrillation (AF) remains a therapeutic challenge in a significant subset of patients. While success rates have improved with repeat AF ablation procedures and the concurrent use of antiarrhythmic drugs, the likelihood of maintaining sinus rhythm during long-term follow-up is still limited. Atrioventricular node ablation (AVNA) has returned as a valuable treatment option given the recent developments in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 14:ehae656. doi: 10.1093/eurheartj/ehae656. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite key advances in catheter-based treatments, the management of persistent atrial fibrillation (AF) remains a therapeutic challenge in a significant subset of patients. While success rates have improved with repeat AF ablation procedures and the concurrent use of antiarrhythmic drugs, the likelihood of maintaining sinus rhythm during long-term follow-up is still limited. Atrioventricular node ablation (AVNA) has returned as a valuable treatment option given the recent developments in cardiac pacing. With the advent of conduction system pacing, AVNA has seen a revival where pacing-induced cardiomyopathy after AVNA is felt to be overcome. This review will discuss the role of permanent pacemaker implantation and AVNA for AF management in this new era of conduction system pacing. Specifically, this review will discuss the haemodynamic consequences of AF and the mechanisms through which 'pace-and-ablate therapy' enhances outcomes, analyse historical and more recent literature across various pacing methods, and work to identify patient groups that may benefit from earlier implementation of this approach.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39397777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39397777</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae656>10.1093/eurheartj/ehae656</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39397777</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jacqueline Joza</dc:creator>
<dc:creator>Haran Burri</dc:creator>
<dc:creator>Jason G Andrade</dc:creator>
<dc:creator>Dominik Linz</dc:creator>
<dc:creator>Kenneth A Ellenbogen</dc:creator>
<dc:creator>Kevin Vernooy</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrioventricular node ablation for atrial fibrillation in the era of conduction system pacing</dc:title>
<dc:identifier>pmid:39397777</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae656</dc:identifier>
</item>
<item>
<title>Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39397661/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>Cardiac arrhythmias are commonly noted in patients during infections with and recovery from COVID-19. Arrhythmic manifestations span the spectrum of innocuous and benign to life-threatening and deadly. Various pathophysiological mechanisms have been proposed. Debate continues on the impact of incident and exacerbated arrhythmias on the acute and chronic (recovery) phase of the illness. COVID-19 and COVID-19 vaccine-associated myocardial inflammation and autonomic disruption remain concerns. As...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 14. doi: 10.1161/CIR.0000000000001290. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiac arrhythmias are commonly noted in patients during infections with and recovery from COVID-19. Arrhythmic manifestations span the spectrum of innocuous and benign to life-threatening and deadly. Various pathophysiological mechanisms have been proposed. Debate continues on the impact of incident and exacerbated arrhythmias on the acute and chronic (recovery) phase of the illness. COVID-19 and COVID-19 vaccine-associated myocardial inflammation and autonomic disruption remain concerns. As the pandemic has transformed to an endemic, with discovery of new SARS-CoV-2 variants, updated vaccines, and potent antiviral drugs, vigilance for COVID-19-associated arrhythmic and dysautonomic manifestations remains. The objective of this American Heart Association scientific statement is to review the available evidence on the epidemiology, pathophysiology, clinical presentation, and management of cardiac arrhythmias and autonomic dysfunction in patients infected with and recovering from COVID-19 and to provide evidence-based guidance. The writing committee's consensus on implications for clinical practice, gaps in knowledge, and directions for future research are highlighted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39397661/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39397661</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001290>10.1161/CIR.0000000000001290</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39397661</guid>
<pubDate>Mon, 14 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Rakesh Gopinathannair</dc:creator>
<dc:creator>Brian Olshansky</dc:creator>
<dc:creator>Mina K Chung</dc:creator>
<dc:creator>Steve Gordon</dc:creator>
<dc:creator>Jose A Joglar</dc:creator>
<dc:creator>Gregory M Marcus</dc:creator>
<dc:creator>Philip L Mar</dc:creator>
<dc:creator>Andrea M Russo</dc:creator>
<dc:creator>Uma N Srivatsa</dc:creator>
<dc:creator>Elaine Y Wan</dc:creator>
<dc:creator>American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Genomic and Precision Medicine; and Council on Hypertension</dc:creator>
<dc:date>2024-10-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39397661</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001290</dc:identifier>
</item>
<item>
<title>The Effect of Teleprehabilitation on Adverse Events After Elective Cardiac Surgery: A Randomized Controlled Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39396714/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Multimodal personalized teleprehabilitation resulted in a clinically relevant and statistically significant reduction of the primary endpoint in patients undergoing cardiac surgery.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 8:S0735-1097(24)09919-4. doi: 10.1016/j.jacc.2024.10.064. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients scheduled for cardiac surgery and procedures often present with modifiable risk factors for adverse perioperative outcomes. Prehabilitation has shown potential to enhance mental and physical fitness however, its effect on clinical cardiovascular endpoints in this population has not been studied.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The current trial was designed to evaluate the effect of a personalized multimodal teleprehabilitation on the incidence of composite endpoint on major adverse cardiovascular events (MACE) in patients scheduled for elective cardiac surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a multicentre randomized controlled trial, 394 patients awaiting elective cardiac surgery and procedures were enrolled. Of these, 197 patients were randomized to an online multimodal personalized teleprehabilitation program through shared-decision making by a multidisciplinary team, and 197 were assigned to a control group. The primary outcome was MACE, (i.e., cardiovascular death, myocardial infarction, stroke, hospitalization for heart failure or other life-threatening cardiac events, and earlier or repeated intervention), as measured from the randomization until 1-year postoperatively. All events were adjudicated by a blinded event committee. Secondary outcomes included length of hospital stay, postoperative complications, quality of life, adherence to the program, and effect on the incidence of modifiable risk factors. Sensitivity analyses of the primary outcome were conducted adjusting for baseline characteristics to evaluate the consistency of treatment effects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From randomization until one year postoperatively, the primary endpoint occurred in 33 patients (16.8%) in the teleprehabilitation group and 50 patients (25.5%) in the control group (difference 8.8%; 95% confidence interval (CI) 0.7 to 16.8; P=0.032). This difference was primarily driven by a reduction in hospitalizations and the sensitivity analyses showed that treatment effect was mainly in the patients undergoing a cardiac surgery rather than transcatheter procedures with adjusted odds ratio of 0.54 (95% CI, 0.30-0.96; P = 0.035). Teleprehabilitation also reduced the incidence of active smokers, elevated pulmonary risk scores, and elevated depression scores. There was no significant difference in postoperative length of hospital stay, occurrence of postoperative complications, physical fitness, incidence of obesity, or malnutrition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Multimodal personalized teleprehabilitation resulted in a clinically relevant and statistically significant reduction of the primary endpoint in patients undergoing cardiac surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov (NCT04393636).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39396714/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39396714</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.064>10.1016/j.jacc.2024.10.064</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39396714</guid>
<pubDate>Sun, 13 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Bart Scheenstra</dc:creator>
<dc:creator>Lieke van Susante</dc:creator>
<dc:creator>Bart C Bongers</dc:creator>
<dc:creator>Ton Lenssen</dc:creator>
<dc:creator>Henriette Knols</dc:creator>
<dc:creator>Sander van Kuijk</dc:creator>
<dc:creator>Maxime Nieman</dc:creator>
<dc:creator>Jos Maessen</dc:creator>
<dc:creator>Arnoud Van't Hof</dc:creator>
<dc:creator>Peyman Sardari Nia</dc:creator>
<dc:creator>Digital Cardiac Counseling (DCC) Trial investigators</dc:creator>
<dc:date>2024-10-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Effect of Teleprehabilitation on Adverse Events After Elective Cardiac Surgery: A Randomized Controlled Trial</dc:title>
<dc:identifier>pmid:39396714</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.064</dc:identifier>
</item>
<item>
<title>Optimizing AHA/ACC Guidelines for the Digital Age: Guidelines in Evolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39396366/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 4:S0735-1097(24)07844-6. doi: 10.1016/j.jacc.2024.07.007. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39396366/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39396366</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.007>10.1016/j.jacc.2024.07.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39396366</guid>
<pubDate>Sun, 13 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Catherine M Otto</dc:creator>
<dc:creator>Mariell Jessup</dc:creator>
<dc:creator>Richard J Kovacs</dc:creator>
<dc:creator>Joshua A Beckman</dc:creator>
<dc:date>2024-10-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Optimizing AHA/ACC Guidelines for the Digital Age: Guidelines in Evolution</dc:title>
<dc:identifier>pmid:39396366</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.007</dc:identifier>
</item>
<item>
<title>Structural basis of respiratory complex adaptation to cold temperatures</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39395414/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>In response to cold, mammals activate brown fat for respiratory-dependent thermogenesis reliant on the electron transport chain. Yet, the structural basis of respiratory complex adaptation upon cold exposure remains elusive. Herein, we combined thermoregulatory physiology and cryoelectron microscopy (cryo-EM) to study endogenous respiratory supercomplexes from mice exposed to different temperatures. A cold-induced conformation of CI:III(2) (termed type 2) supercomplex was identified with a ∼25°...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 3:S0092-8674(24)01087-0. doi: 10.1016/j.cell.2024.09.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In response to cold, mammals activate brown fat for respiratory-dependent thermogenesis reliant on the electron transport chain. Yet, the structural basis of respiratory complex adaptation upon cold exposure remains elusive. Herein, we combined thermoregulatory physiology and cryoelectron microscopy (cryo-EM) to study endogenous respiratory supercomplexes from mice exposed to different temperatures. A cold-induced conformation of CI:III<sub>2</sub> (termed type 2) supercomplex was identified with a ∼25° rotation of CIII<sub>2</sub> around its inter-dimer axis, shortening inter-complex Q exchange space, and exhibiting catalytic states that favor electron transfer. Large-scale supercomplex simulations in mitochondrial membranes reveal how lipid-protein arrangements stabilize type 2 complexes to enhance catalytic activity. Together, our cryo-EM studies, multiscale simulations, and biochemical analyses unveil the thermoregulatory mechanisms and dynamics of increased respiratory capacity in brown fat at the structural and energetic level.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39395414/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39395414</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.029>10.1016/j.cell.2024.09.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39395414</guid>
<pubDate>Sat, 12 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Young-Cheul Shin</dc:creator>
<dc:creator>Pedro Latorre-Muro</dc:creator>
<dc:creator>Amina Djurabekova</dc:creator>
<dc:creator>Oleksii Zdorevskyi</dc:creator>
<dc:creator>Christopher F Bennett</dc:creator>
<dc:creator>Nils Burger</dc:creator>
<dc:creator>Kangkang Song</dc:creator>
<dc:creator>Chen Xu</dc:creator>
<dc:creator>Joao A Paulo</dc:creator>
<dc:creator>Steven P Gygi</dc:creator>
<dc:creator>Vivek Sharma</dc:creator>
<dc:creator>Maofu Liao</dc:creator>
<dc:creator>Pere Puigserver</dc:creator>
<dc:date>2024-10-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structural basis of respiratory complex adaptation to cold temperatures</dc:title>
<dc:identifier>pmid:39395414</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.029</dc:identifier>
</item>
<item>
<title>Genome integrity sensing by the broad-spectrum Hachiman antiphage defense complex</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39395413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>Hachiman is a broad-spectrum antiphage defense system of unknown function. We show here that Hachiman is a heterodimeric nuclease-helicase complex, HamAB. HamA, previously a protein of unknown function, is the effector nuclease. HamB is the sensor helicase. HamB constrains HamA activity during surveillance of intact double-stranded DNA (dsDNA). When the HamAB complex detects DNA damage, HamB helicase activity activates HamA, unleashing nuclease activity. Hachiman activation degrades all DNA in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 3:S0092-8674(24)01068-7. doi: 10.1016/j.cell.2024.09.020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hachiman is a broad-spectrum antiphage defense system of unknown function. We show here that Hachiman is a heterodimeric nuclease-helicase complex, HamAB. HamA, previously a protein of unknown function, is the effector nuclease. HamB is the sensor helicase. HamB constrains HamA activity during surveillance of intact double-stranded DNA (dsDNA). When the HamAB complex detects DNA damage, HamB helicase activity activates HamA, unleashing nuclease activity. Hachiman activation degrades all DNA in the cell, creating "phantom" cells devoid of both phage and host DNA. We demonstrate Hachiman activation in the absence of phage by treatment with DNA-damaging agents, suggesting that Hachiman responds to aberrant DNA states. Phylogenetic similarities between the Hachiman helicase and enzymes from eukaryotes and archaea suggest deep functional symmetries with other important helicases across domains of life.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39395413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39395413</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.020>10.1016/j.cell.2024.09.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39395413</guid>
<pubDate>Sat, 12 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Owen T Tuck</dc:creator>
<dc:creator>Benjamin A Adler</dc:creator>
<dc:creator>Emily G Armbruster</dc:creator>
<dc:creator>Arushi Lahiri</dc:creator>
<dc:creator>Jason J Hu</dc:creator>
<dc:creator>Julia Zhou</dc:creator>
<dc:creator>Joe Pogliano</dc:creator>
<dc:creator>Jennifer A Doudna</dc:creator>
<dc:date>2024-10-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Genome integrity sensing by the broad-spectrum Hachiman antiphage defense complex</dc:title>
<dc:identifier>pmid:39395413</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.020</dc:identifier>
</item>
<item>
<title>Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39394525/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>Dilated cardiomyopathy (DCM) is a complex disease with multiple causes and various pathogenic mechanisms. Despite improvements in the prognosis of patients with DCM in the past decade, this condition remains a leading cause of heart failure and premature death. Conventional treatment for DCM is based on the foundational therapies for heart failure with reduced ejection fraction. However, increasingly, attention is being directed towards individualized treatments and precision medicine. The...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 11. doi: 10.1038/s41569-024-01074-2. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Dilated cardiomyopathy (DCM) is a complex disease with multiple causes and various pathogenic mechanisms. Despite improvements in the prognosis of patients with DCM in the past decade, this condition remains a leading cause of heart failure and premature death. Conventional treatment for DCM is based on the foundational therapies for heart failure with reduced ejection fraction. However, increasingly, attention is being directed towards individualized treatments and precision medicine. The ability to confirm genetic causality is gradually being complemented by an increased understanding of genotype-phenotype correlations. Non-genetic factors also influence the onset of DCM, and growing evidence links genetic background with concomitant non-genetic triggers or precipitating factors, increasing the extreme complexity of the pathophysiology of DCM. This Review covers the spectrum of pathophysiological mechanisms in DCM, from monogenic causes to the coexistence of genetic abnormalities and triggering environmental factors (the 'two-hit' hypothesis). The roles of common genetic variants in the general population and of gene modifiers in disease onset and progression are also discussed. Finally, areas for future research are highlighted, particularly novel therapies, such as small molecules, RNA and gene therapy, and measures for the prevention of arrhythmic death.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39394525/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39394525</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01074-2>10.1038/s41569-024-01074-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39394525</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Marta Gigli</dc:creator>
<dc:creator>Davide Stolfo</dc:creator>
<dc:creator>Marco Merlo</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Matthew R G Taylor</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine</dc:title>
<dc:identifier>pmid:39394525</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01074-2</dc:identifier>
</item>
<item>
<title>Clinical and subclinical acute brain injury caused by invasive cardiovascular procedures</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39394524/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>Over the past 50 years, the number and invasiveness of percutaneous cardiovascular procedures globally have increased substantially. However, cardiovascular interventions are inherently associated with a risk of acute brain injury, both periprocedurally and postprocedurally, which impairs medical outcomes and increases health-care costs. Current international clinical guidelines generally do not cover the area of acute brain injury related to cardiovascular invasive procedures. In this...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 11. doi: 10.1038/s41569-024-01076-0. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Over the past 50 years, the number and invasiveness of percutaneous cardiovascular procedures globally have increased substantially. However, cardiovascular interventions are inherently associated with a risk of acute brain injury, both periprocedurally and postprocedurally, which impairs medical outcomes and increases health-care costs. Current international clinical guidelines generally do not cover the area of acute brain injury related to cardiovascular invasive procedures. In this international Consensus Statement, we compile the available knowledge (including data on prevalence, pathophysiology, risk factors, clinical presentation and management) to formulate consensus recommendations on the prevention, diagnosis and treatment of acute brain injury caused by cardiovascular interventions. We also identify knowledge gaps and possible future directions in clinical research into acute brain injury related to cardiovascular interventions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39394524/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39394524</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01076-0>10.1038/s41569-024-01076-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39394524</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Radosław Lenarczyk</dc:creator>
<dc:creator>Marco Proietti</dc:creator>
<dc:creator>Jan F Scheitz</dc:creator>
<dc:creator>Dipen Shah</dc:creator>
<dc:creator>Eberhard Siebert</dc:creator>
<dc:creator>Diana A Gorog</dc:creator>
<dc:creator>Jacek Kowalczyk</dc:creator>
<dc:creator>Nikolaos Bonaros</dc:creator>
<dc:creator>George Ntaios</dc:creator>
<dc:creator>Wolfram Doehner</dc:creator>
<dc:creator>Nicolas M Van Mieghem</dc:creator>
<dc:creator>Sandor Nardai</dc:creator>
<dc:creator>Jan Kovac</dc:creator>
<dc:creator>Roland Fiszer</dc:creator>
<dc:creator>Roberto Lorusso</dc:creator>
<dc:creator>Eliano Navarese</dc:creator>
<dc:creator>Sergio Castrejón</dc:creator>
<dc:creator>Andrea Rubboli</dc:creator>
<dc:creator>José Miguel Rivera-Caravaca</dc:creator>
<dc:creator>Alaide Chieffo</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Clinical and subclinical acute brain injury caused by invasive cardiovascular procedures</dc:title>
<dc:identifier>pmid:39394524</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01076-0</dc:identifier>
</item>
<item>
<title>Correction to: Great debate: myocardial infarction after cardiac surgery must be redefined</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392465/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 11:ehae734. doi: 10.1093/eurheartj/ehae734. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392465/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39392465</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae734>10.1093/eurheartj/ehae734</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392465</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Great debate: myocardial infarction after cardiac surgery must be redefined</dc:title>
<dc:identifier>pmid:39392465</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae734</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: FINEARTS-HF supports the role of aldosterone antagonism in the management of heart failure with mildly reduced or preserved ejection fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 11:ehae679. doi: 10.1093/eurheartj/ehae679. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39392246</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae679>10.1093/eurheartj/ehae679</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392246</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Massimo Volpe</dc:creator>
<dc:creator>Leonarda Galiuto</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: FINEARTS-HF supports the role of aldosterone antagonism in the management of heart failure with mildly reduced or preserved ejection fraction</dc:title>
<dc:identifier>pmid:39392246</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae679</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: is MATTERHORN a game changer for secondary mitral regurgitation? Still climbing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392244/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 11:ehae650. doi: 10.1093/eurheartj/ehae650. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392244/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39392244</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae650>10.1093/eurheartj/ehae650</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392244</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: is MATTERHORN a game changer for secondary mitral regurgitation? Still climbing</dc:title>
<dc:identifier>pmid:39392244</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae650</dc:identifier>
</item>
<item>
<title>Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392008/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: ANGPTL3/8 potently inhibited GPIHBP1-LPL enzymatic activity, consistent with its positive association with serum lipids. However, ANGPTL3/8, LDL-C, and triglyceride levels were not associated with cardiovascular death in the LURIC and getABI cohorts. In contrast, concentrations of ANGPTL4/8 and particularly CD-ANGPTL4 were positively associated with inflammation, the prevalence of diabetes, and cardiovascular mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 11. doi: 10.1161/CIRCULATIONAHA.124.069272. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: ANGPTL3/4/8 (angiopoietin-like proteins 3, 4, and 8) are important regulators of LPL (lipoprotein lipase). ANGPTL8 forms complexes with ANGPTL3 and ANGPTL4. ANGPTL4/8 complex formation converts ANGPTL4 from a furin substrate to a plasmin substrate, and both cleavages generate similar C-terminal domain-containing (CD)-ANGPTL4 fragments. Whereas several studies have investigated associations of free ANGPTL proteins with cardiovascular risk, there are no data describing associations of the complexes and CD-ANGPTL4 with outcomes or describing the effects of the complexes on LPL bound to GPIHBP1 (glycosylphosphatidylinositol HDL-binding protein 1).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Recombinant protein assays were used to study ANGPTL protein and complex effects on GPIHBP1-LPL activity. ANGPTL3/8, ANGPTL3, ANGPTL4/8, and CD-ANGPTL4 were measured with dedicated immunoassays in 2394 LURIC (Ludwigshafen Risk and Cardiovascular Health) study participants undergoing coronary angiography and 6188 getABI study (German Epidemiological Trial on Ankle Brachial Index) participants undergoing ankle brachial index measurement. There was a follow-up for cardiovascular death with a median (interquartile range) duration of 9.80 (8.75-10.40) years in the LURIC study and 7.06 (7.00-7.14) years in the getABI study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: ANGPTL3/8 potently inhibited GPIHBP1-LPL activity and showed positive associations with LDL-C (low-density lipoprotein cholesterol) and triglycerides (both <i>P</i>&lt;0.001). However, in neither study did ANGPTL3/8 correlate with cardiovascular death. Free ANGPTL3 was positively associated with cardiovascular death in the getABI study but not the LURIC study. ANGPTL4/8 and especially CD-ANGPTL4 were positively associated with the prevalence of diabetes, CRP (C-reactive protein; all <i>P</i>&lt;0.001), and cardiovascular death in both studies. In the LURIC and getABI studies, respective hazard ratios for cardiovascular mortality comparing the third with the first ANGPTL4/8 tertile were 1.47 (1.15-1.88) and 1.68 (1.25-2.27) when adjusted for sex, age, body mass index, and diabetes. For CD-ANGPTL4, these hazard ratios were 2.44 (1.86-3.20) and 2.76 (2.00-3.82).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: ANGPTL3/8 potently inhibited GPIHBP1-LPL enzymatic activity, consistent with its positive association with serum lipids. However, ANGPTL3/8, LDL-C, and triglyceride levels were not associated with cardiovascular death in the LURIC and getABI cohorts. In contrast, concentrations of ANGPTL4/8 and particularly CD-ANGPTL4 were positively associated with inflammation, the prevalence of diabetes, and cardiovascular mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392008/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39392008</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069272>10.1161/CIRCULATIONAHA.124.069272</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392008</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Günther Silbernagel</dc:creator>
<dc:creator>Yan Q Chen</dc:creator>
<dc:creator>Hongxia Li</dc:creator>
<dc:creator>Deven Lemen</dc:creator>
<dc:creator>Yi Wen</dc:creator>
<dc:creator>Eugene Y Zhen</dc:creator>
<dc:creator>Martin Rief</dc:creator>
<dc:creator>Marcus E Kleber</dc:creator>
<dc:creator>Graciela Delgado</dc:creator>
<dc:creator>Mark A Sarzynski</dc:creator>
<dc:creator>Yue-Wei Qian</dc:creator>
<dc:creator>Boerge Schmidt</dc:creator>
<dc:creator>Raimund Erbel</dc:creator>
<dc:creator>Ulrike Trampisch</dc:creator>
<dc:creator>Angela P Moissl</dc:creator>
<dc:creator>Henrik Rudolf</dc:creator>
<dc:creator>Heribert Schunkert</dc:creator>
<dc:creator>Andreas Stang</dc:creator>
<dc:creator>Winfried März</dc:creator>
<dc:creator>Hans J Trampisch</dc:creator>
<dc:creator>Hubert Scharnagl</dc:creator>
<dc:creator>Robert J Konrad</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality</dc:title>
<dc:identifier>pmid:39392008</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069272</dc:identifier>
</item>
<item>
<title>YAP Overcomes Mechanical Barriers to Induce Mitotic Rounding and Adult Cardiomyocyte Division</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our data reveal that YAP5SA overcomes the mechanically constrained myocardial microenvironment to induce mitotic rounding with cardiomyocyte division, thus providing new insights into the in vivo mechanisms that maintain cell cycle quiescence in adult mammals.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 11. doi: 10.1161/CIRCULATIONAHA.123.066004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Many specialized cells in adult organs acquire a state of cell cycle arrest and quiescence through unknown mechanisms. Our limited understanding of mammalian cell cycle arrest is derived primarily from cell culture models. Adult mammalian cardiomyocytes, a classic example of cell cycle arrested cells, exit the cell cycle postnatally and remain in an arrested state for the life of the organism. Cardiomyocytes can be induced to re-enter the cell cycle by YAP5SA, an active form of the Hippo signaling pathway effector YAP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed clonal analyses to determine the cell kinetics of YAP5SA cardiomyocytes. We also performed single-cell RNA sequencing, marker gene analysis, and functional studies to examine how YAP5SA cardiomyocytes progress through the cell cycle.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We discovered that YAP5SA-expressing cardiomyocytes divided efficiently, with >;20% of YAP5SA cardiomyocyte clones containing ≥2 cardiomyocytes. YAP5SA cardiomyocytes re-entered cell cycle at the G1/S transition and had an S phase lasting ≈48 hours. Sarcomere disassembly is required for cardiomyocyte progression from S to G2 phase and the induction of mitotic rounding. Although oscillatory Cdk expression was induced in YAP5SA cardiomyocytes, these cells inefficiently progressed through G2 phase. This is improved by inhibiting P21 function, implicating checkpoint activity as an additional barrier to YAP5SA-induced cardiomyocyte division.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our data reveal that YAP5SA overcomes the mechanically constrained myocardial microenvironment to induce mitotic rounding with cardiomyocyte division, thus providing new insights into the in vivo mechanisms that maintain cell cycle quiescence in adult mammals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39392007</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066004>10.1161/CIRCULATIONAHA.123.066004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392007</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Yuka Morikawa</dc:creator>
<dc:creator>Jong H Kim</dc:creator>
<dc:creator>Rich Gang Li</dc:creator>
<dc:creator>Lin Liu</dc:creator>
<dc:creator>Shijie Liu</dc:creator>
<dc:creator>Vaibhav Deshmukh</dc:creator>
<dc:creator>Matthew C Hill</dc:creator>
<dc:creator>James F Martin</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>YAP Overcomes Mechanical Barriers to Induce Mitotic Rounding and Adult Cardiomyocyte Division</dc:title>
<dc:identifier>pmid:39392007</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066004</dc:identifier>
</item>
<item>
<title>A Rare Noncoding Enhancer Variant in &lt;em>;SCN5A&lt;/em>; Contributes to the High Prevalence of Brugada Syndrome in Thailand</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39391988/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This is the first example of a functionally validated rare noncoding variant at the SCN5A locus and highlights how genome sequencing in understudied populations can identify novel disease mechanisms. The variant partly explains the increased prevalence of BrS in this region and enables the identification of at-risk variant carriers to reduce the burden of sudden cardiac death in Thailand.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 11. doi: 10.1161/CIRCULATIONAHA.124.069041. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Brugada syndrome (BrS) is a cardiac arrhythmia disorder that causes sudden death in young adults. Rare genetic variants in the <i>SCN5A</i> gene encoding the Na<sub>v</sub>1.5 sodium channel and common noncoding variants at this locus are robustly associated with the condition. BrS is particularly prevalent in Southeast Asia but the underlying ancestry-specific factors remain largely unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Genome sequencing of BrS probands and population-matched controls from Thailand was performed to identify rare noncoding variants at the <i>SCN5A-SCN10A</i> locus that were enriched in patients with BrS. A likely causal variant was prioritized by computational methods and introduced into human induced pluripotent stem cell (hiPSC) lines using CRISPR-Cas9. The effect of the variant on <i>SCN5A</i> expression and Na<sub>v</sub>1.5 sodium channel current was then assessed in hiPSC-derived cardiomyocytes (hiPSC-CMs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A rare noncoding variant in an <i>SCN5A</i> intronic enhancer region was highly enriched in patients with BrS (detected in 3.9% of cases with a case-control odds ratio of 45.2). The variant affects a nucleotide conserved across all mammalian species and predicted to disrupt a Mef2 transcription factor binding site. Heterozygous introduction of the enhancer variant in hiPSC-CMs caused significantly reduced <i>SCN5A</i> expression from the variant-containing allele and a 30% reduction in Na<sub>v</sub>1.5-mediated sodium current density compared with isogenic controls, confirming its pathogenicity. Patients with the variant had severe phenotypes, with 89% experiencing cardiac arrest.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This is the first example of a functionally validated rare noncoding variant at the <i>SCN5A</i> locus and highlights how genome sequencing in understudied populations can identify novel disease mechanisms. The variant partly explains the increased prevalence of BrS in this region and enables the identification of at-risk variant carriers to reduce the burden of sudden cardiac death in Thailand.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39391988/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39391988</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069041>10.1161/CIRCULATIONAHA.124.069041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39391988</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Roddy Walsh</dc:creator>
<dc:creator>John Mauleekoonphairoj</dc:creator>
<dc:creator>Isabella Mengarelli</dc:creator>
<dc:creator>Fernanda M Bosada</dc:creator>
<dc:creator>Arie O Verkerk</dc:creator>
<dc:creator>Karel van Duijvenboden</dc:creator>
<dc:creator>Yong Poovorawan</dc:creator>
<dc:creator>Wanwarang Wongcharoen</dc:creator>
<dc:creator>Boosamas Sutjaporn</dc:creator>
<dc:creator>Pharawee Wandee</dc:creator>
<dc:creator>Nitinan Chimparlee</dc:creator>
<dc:creator>Ronpichai Chokesuwattanaskul</dc:creator>
<dc:creator>Kornkiat Vongpaisarnsin</dc:creator>
<dc:creator>Piyawan Dangkao</dc:creator>
<dc:creator>Cheng-I Wu</dc:creator>
<dc:creator>Rafik Tadros</dc:creator>
<dc:creator>Ahmad S Amin</dc:creator>
<dc:creator>Krystien V V Lieve</dc:creator>
<dc:creator>Pieter G Postema</dc:creator>
<dc:creator>Maarten Kooyman</dc:creator>
<dc:creator>Leander Beekman</dc:creator>
<dc:creator>Dujdao Sahasatas</dc:creator>
<dc:creator>Montawatt Amnueypol</dc:creator>
<dc:creator>Rungroj Krittayaphong</dc:creator>
<dc:creator>Somchai Prechawat</dc:creator>
<dc:creator>Alisara Anannab</dc:creator>
<dc:creator>Pattarapong Makarawate</dc:creator>
<dc:creator>Tachapong Ngarmukos</dc:creator>
<dc:creator>Keerapa Phusanti</dc:creator>
<dc:creator>Gumpanart Veerakul</dc:creator>
<dc:creator>Zoya Kingsbury</dc:creator>
<dc:creator>Taksina Newington</dc:creator>
<dc:creator>Uma Maheswari</dc:creator>
<dc:creator>Mark T Ross</dc:creator>
<dc:creator>Andrew Grace</dc:creator>
<dc:creator>Pier D Lambiase</dc:creator>
<dc:creator>Elijah R Behr</dc:creator>
<dc:creator>Jean-Jacques Schott</dc:creator>
<dc:creator>Richard Redon</dc:creator>
<dc:creator>Julien Barc</dc:creator>
<dc:creator>Vincent M Christoffels</dc:creator>
<dc:creator>Arthur A M Wilde</dc:creator>
<dc:creator>Koonlawee Nademanee</dc:creator>
<dc:creator>Connie R Bezzina</dc:creator>
<dc:creator>Apichai Khongphatthanayothin</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Rare Noncoding Enhancer Variant in &lt;em>;SCN5A&lt;/em>; Contributes to the High Prevalence of Brugada Syndrome in Thailand</dc:title>
<dc:identifier>pmid:39391988</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069041</dc:identifier>
</item>
<item>
<title>Brugada Syndrome Risk Stratification: Selecting the Population of Interest</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39387765/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 2:S0735-1097(24)08508-5. doi: 10.1016/j.jacc.2024.08.076. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39387765/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39387765</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.076>10.1016/j.jacc.2024.08.076</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39387765</guid>
<pubDate>Thu, 10 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael Litt</dc:creator>
<dc:creator>Rajat Deo</dc:creator>
<dc:date>2024-10-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Brugada Syndrome Risk Stratification: Selecting the Population of Interest</dc:title>
<dc:identifier>pmid:39387765</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.076</dc:identifier>
</item>
<item>
<title>Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39387764/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Recaticimab monotherapy yielded significant LDL-C reductions and showed comparable safety vs placebo in patients with nonfamilial hypercholesterolemia and mixed hyperlipemia at low-to-moderate ASCVD risk, even with an infrequent dosing interval up to Q12W.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 2:S0735-1097(24)08037-9. doi: 10.1016/j.jacc.2024.07.035. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9) have been used to reduce the level of low-density lipoprotein cholesterol (LDL-C), but require either biweekly or monthly dosing frequency. Recaticimab is a new humanized monoclonal antibody selectively targeting PCSK9, with long-acting characteristic.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to assess the efficacy and safety of recaticimab monotherapy in patients with nonfamilial hypercholesterolemia and mixed hyperlipemia at low-to-moderate atherosclerotic cardiovascular disease (ASCVD) risk, and to explore different dosing strategies to provide patients with flexible administration options.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a randomized, double-blind, placebo-controlled, phase 3 study conducted at 59 sites in China. Patients with fasting LDL-C ≥2.6 to &lt;4.9 mmol/L, fasting triglyceride ≤5.6 mmol/L, and 10-year ASCVD risk score &lt;10% were randomly assigned (2:2:2:1:1:1) to receive subcutaneous injections of recaticimab at 150 mg every 4 weeks (Q4W), 300 mg every 8 weeks (Q8W), or 450 mg every 12 weeks (Q12W), or matching placebo, on background lipid-lowering diet. Primary endpoint was percentage change in LDL-C from baseline to week 12 for 150 mg Q4W and 450 mg Q12W and to week 16 for 300 mg Q8W.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 703 patients underwent randomization and received recaticimab (n = 157, 156, and 155 for 150 mg Q4W, 300 mg Q8W, and 450 mg Q12W, respectively) or placebo (n = 78, 79, and 78, respectively). Compared with placebo, recaticimab further reduced LDL-C by 49.6% (95% CI: 44.2%-54.9%) at 150 mg Q4W, 52.8% (95% CI: 48.3%-57.2%) at 300 mg Q8W, and 45.0% (95% CI: 41.0%-49.0%) at 450 mg Q12W (P &lt; 0.0001 for all comparisons). Safety with recaticimab was comparable to placebo. After 12 or 16 weeks of treatment, patients who received recaticimab continued treatment until week 24, whereas those allocated to placebo were switched to recaticimab treatment with the same dosing strategy. Both 24-week recaticimab and 12- or 8-week recaticimab switched from placebo were effective. With 24 weeks of recaticimab treatment, the most common treatment-related adverse event was injection site reaction (n = 23 [4.9%]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Recaticimab monotherapy yielded significant LDL-C reductions and showed comparable safety vs placebo in patients with nonfamilial hypercholesterolemia and mixed hyperlipemia at low-to-moderate ASCVD risk, even with an infrequent dosing interval up to Q12W.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39387764/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39387764</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.035>10.1016/j.jacc.2024.07.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39387764</guid>
<pubDate>Thu, 10 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Mingtong Xu</dc:creator>
<dc:creator>Zhen Wang</dc:creator>
<dc:creator>Yumin Zhang</dc:creator>
<dc:creator>Yong Liu</dc:creator>
<dc:creator>Rongjie Huang</dc:creator>
<dc:creator>Xuebin Han</dc:creator>
<dc:creator>Zhuhua Yao</dc:creator>
<dc:creator>Jiao Sun</dc:creator>
<dc:creator>Fengsheng Tian</dc:creator>
<dc:creator>Xitian Hu</dc:creator>
<dc:creator>Liping Ma</dc:creator>
<dc:creator>Chunlin Lai</dc:creator>
<dc:creator>Xiwen Zhang</dc:creator>
<dc:creator>Jianlong Sheng</dc:creator>
<dc:creator>Qinghua Han</dc:creator>
<dc:creator>Chunrong Jin</dc:creator>
<dc:creator>Li Luo</dc:creator>
<dc:creator>Ruiping Zhao</dc:creator>
<dc:creator>Liwen Li</dc:creator>
<dc:creator>Biao Xu</dc:creator>
<dc:creator>Delu Yin</dc:creator>
<dc:creator>Suxin Luo</dc:creator>
<dc:creator>Xiaofeng Ge</dc:creator>
<dc:creator>Zhiyuan Liu</dc:creator>
<dc:creator>Ping Yang</dc:creator>
<dc:creator>Zheng Huang</dc:creator>
<dc:creator>Tianfa Li</dc:creator>
<dc:creator>Wei Feng</dc:creator>
<dc:creator>Yanqing Wu</dc:creator>
<dc:creator>Zhiyu Ling</dc:creator>
<dc:creator>Likun Ma</dc:creator>
<dc:creator>Chao Lv</dc:creator>
<dc:creator>Chanjuan Deng</dc:creator>
<dc:creator>Wenhua Wei</dc:creator>
<dc:creator>Ying Wang</dc:creator>
<dc:creator>Li Yan</dc:creator>
<dc:creator>JunBo Ge</dc:creator>
<dc:creator>REMAIN-1 Investigators</dc:creator>
<dc:date>2024-10-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial</dc:title>
<dc:identifier>pmid:39387764</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.035</dc:identifier>
</item>
<item>
<title>Using Selection Criteria From the DanGer Shock Trial in a Contemporary Cohort With Cardiogenic Shock</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39387763/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 2:S0735-1097(24)08387-6. doi: 10.1016/j.jacc.2024.08.056. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39387763/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39387763</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.056>10.1016/j.jacc.2024.08.056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39387763</guid>
<pubDate>Thu, 10 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Connor G O'Brien</dc:creator>
<dc:creator>Samuel B Brusca</dc:creator>
<dc:creator>Christopher F Barnett</dc:creator>
<dc:creator>David D Berg</dc:creator>
<dc:creator>Vivian M Baird-Zars</dc:creator>
<dc:creator>Jeong-Gun Park</dc:creator>
<dc:creator>Erin A Bohula</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>CCCTN Investigators</dc:creator>
<dc:date>2024-10-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Using Selection Criteria From the DanGer Shock Trial in a Contemporary Cohort With Cardiogenic Shock</dc:title>
<dc:identifier>pmid:39387763</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.056</dc:identifier>
</item>
<item>
<title>A Step Forward for Long-Acting PCSK9 Inhibition: Improvements Without a Breakthrough</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39387762/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241014141401&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 2:S0735-1097(24)08513-9. doi: 10.1016/j.jacc.2024.09.019. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39387762/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241014141401&v=2.18.0.post9+e462414">39387762</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.019>10.1016/j.jacc.2024.09.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39387762</guid>
<pubDate>Thu, 10 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Raul D Santos</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>Michael D Shapiro</dc:creator>
<dc:date>2024-10-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Step Forward for Long-Acting PCSK9 Inhibition: Improvements Without a Breakthrough</dc:title>
<dc:identifier>pmid:39387762</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.019</dc:identifier>
</item>





























</channel>
</rss>